The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Small transaction, but still another deal
Miromatrix Medical Inc.'s stock (MIRO) jumped 230% in premarket trades on Monday after the company agreed to be acquired by United Therapeutics Corp. (UTHR) for $3.25 per share in cash, or about $91 million.
Please use the sharing tools found via the share button at the top or side of articles. Copying articles to share with others is a breach of FT.com T&Cs and Copyright Policy. Email licensing@ft.com to buy additional rights. Subscribers may share up to 10 or 20 articles per month using the gift article service. More information can be found at https://www.ft.com/tour.
https://www.ft.com/content/6f12dad4-dc09-4bb5-b1c7-941eb2408bac
Shares in Sanofi fell 15 per cent on Friday after the French pharmaceutical group announced a lower profit outlook and a spinout of its consumer care unit as it seeks to focus investment in drug research.
Sanofi’s shares down 20%, however this another company who have expressed strong interest in precision medicine!
A new report from Tufts Medical Center’s New Drug Development Paradigms (NEWDIGS) program shows that cell and gene therapies for orphan diseases and hematological cancers are two to 3.5 times more likely to be successful than other types of treatments for similar conditions, or as compared to the entire drug pipeline.
CAR-T/TCR therapies for blood cancers were three times more likely to be approved when entering phase 1 compared to the average oncology drug and over two times more likely than the average hematological oncology drug, it concluded.
Listening to Novartis yesterday making it very clear that Radiotherapy was one of their key growth areas, in Avacta’s case, the majors only have one problem:
Who goes first ?
However with AVA6000 and AVA3996,Cohort and the rest of the AVA family- Nasdaq could be round the corner sooner rather than later!
NY will be up early and size buyers will step it up a gear.
Watch out for Dr. Tap seen shaking hands with the FDA, two weeks works!!